Physician profile
Laina Feinstein
NPI 1467431031
$8,451.45
in general payments reported to CMS, 2019-2025
48 companies · $541 in 2025
The $541 reported for 2025 was more than what 75% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,441 · 2020: $1,004 · 2021: $1,502 · 2022: $1,095 · 2023: $1,445 · 2024: $1,423 · 2025: $541.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,409.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,408.80 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $847.39 | 2019-2025 | Airsupra, Farxiga, Breztri |
| Abbvie INC. | $805.36 | 2019-2025 | |
| Novo Nordisk INC | $740.75 | 2019-2025 | Rybelsus, Ozempic |
| Glaxosmithkline, LLC. | $490.99 | 2019-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Pfizer INC. | $455.19 | 2019-2025 | |
| Nestle Healthcare Nutrition INC. | $421.70 | 2020-2023 | |
| Merck Sharp & Dohme LLC | $421.37 | 2019-2025 | Verquvo |
| Lilly USA, LLC | $416.94 | 2019-2025 | Mounjaro, Zepbound, Jardiance |
| Novartis Pharmaceuticals Corporation | $368.54 | 2019-2023 | |
| Amgen INC. | $341.28 | 2019-2025 | Repatha, Otezla, Otezla |
| Astellas Pharma US INC | $296.41 | 2019-2024 | Veozah, Myrbetriq |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $217.49 | 2019-2024 | Trulance, Xifaxan |
| Sumitomo Pharma America, INC. | $213.09 | 2023-2025 | Gemtesa |
| Boehringer Ingelheim Pharmaceuticals, INC. | $212.62 | 2019-2025 | Jardiance |
| Ardelyx, INC. | $161.35 | 2023-2025 | Ibsrela |
Show all 48 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Laina Feinstein listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.